# Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

> **NCT05488548** · PHASE1 · RECRUITING · sponsor: **Epigenetix, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Castrate Resistant Prostate Cancer
- NUT Carcinoma
- Chronic Myelomonocytic Leukemia
- Myelofibrosis

## Interventions

- **DRUG:** EP31670

## Key facts

- **NCT ID:** NCT05488548
- **Lead sponsor:** Epigenetix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-21
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488548, "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05488548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*